Third Rock Ventures partner Kevin Starr decided not to stand for re-election as the chairman of Cambridge, MA-based Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]), a company he helped found in 2007. At a shareholder meeting today, Rockefeller University president Marc Tessier-Lavigne was named Starr’s replacement. Tessier-Lavigne was already chairing Agios’s compensation committee. He’s also the chairman of the recently formed Denali Therapeutics. Agios also announced that former Goldman Sachs partner Maykin Ho joined its board.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler